-- マレーシア統計局が金曜日に発表した速報値によると、マレーシア経済は第1四半期に5.3%拡大したが、前四半期の6.3%増から減速した。 四半期ベースでは、経済は4.4%縮小した。これは、2025年第4四半期の3.3%拡大予測とは対照的である。 供給面では、サービス、製造、建設、農業部門の成長が経済を支えたが、鉱業・採石業は縮小した。 サービス部門は、卸売・小売業、情報通信業、運輸・倉庫業の好調に牽引され、5.4%成長した。製造業は、主要サブセクターの生産量増加により5.8%拡大した。 鉱業・採石業は、原油・天然ガス生産量の減少により1.1%縮小した。一方、農業は2.8%、建設業は7.8%増加したが、伸び率は鈍化した。 マレーシア統計局は、第1四半期のGDP速報値を5月15日に発表すると発表した。
Related Articles
Easou Technology Invests $7.7 Million in Wealth Product Using Idle Top-up Placing Funds
Easou Technology (HKG:2550) said it has subscribed to a $7.7 million wealth management product issued by Huatai International Financial Products, using idle proceeds from its earlier placings, according to a Friday Hong Kong bourse filing.Shares of the digital service firm were down over 1% in Monday's late-morning trade.The investment, guaranteed by Huatai International Financial, carries an annualized return of 1.07% to 5.83% over a term ending March 30, 2027.Easou said the move aims to enhance the utilization efficiency and returns on idle funds while maintaining liquidity.
SSY Group Gets Chinese Regulatory Nod for Production, Registration of Two Products
SSY Group (HKG:2005) said it received Chinese regulatory approval to begin drug production and registration of its diltiazem hydrochloride in injection form, according to a Hong Kong bourse filing Monday.The drug is mainly used to treat a heart condition known as supraventricular tachycardia and the emergency treatment of abnormally high blood pressure during surgery.The firm's propranolol hydrochloride injection was also approved for production and registration by China's National Medical Products Administration.The product is mainly used to treat supraventricular tachyarrhythmias and ventricular arrhythmias.
Amplitude Energy Says Australian Retirement Trust Raises Stake
Amplitude Energy (ASX:AEL) said Australian Retirement Trust raised its stake in the firm to 6.3% as of Friday from 5.1% as of April 2, according to a Monday Australian bourse filing.Australian Retirement Trust now holds nearly 19 million votes in the firm.